key: cord-0939418-48zkze2g authors: Sharma, Alok; Shah, Mili; Lakshmi, Satya; Sane, Hemangi; Captain, Jignasha; Gokulchandran, Nandini; Khubchandani, Pallavi; M.K, Pradeep.; Gote, Prakash; Tuppekar, Balaji; Kulkarni, Pooja; Paranjape, Amruta; Pradhan, Radhika; Varghese, Ritu; Kasekar, Sushil; Nair, Vivek; Khanbande, Ummeammara title: A Pilot study for treatment of COVID-19 patients in moderate stage using Intravenous administration of Ozonized saline as an adjuvant treatment- Registered Clinical Trial date: 2021-04-30 journal: Int Immunopharmacol DOI: 10.1016/j.intimp.2021.107743 sha: 5319d17e1cc3309d02b9de3cf869d927ed8a6a4b doc_id: 939418 cord_uid: 48zkze2g Objective Ozone therapy has tremendous therapeutic potential owing to its antiviral, anti-inflammatory and antioxidant properties, and potential to improve oxygenation. A pilot clinical trial was conducted to evaluate the safety and efficacy ofintravenous ozonised saline treatment in patients with moderate COVID-19 pneumonia. Patients and Methods 10 patients were administered 200 ml freshly prepared ozonised saline intravenously over 1 hour once a day for 8 days along with standard medical treatment. Clinical symptoms were monitored everyday and laboratory biomarkers, radiological findings at 1,3,6,10 days. Telephonic follow up was done for all after discharge till Day 14. 7 out of 10 patients required oxygen supplementation at recruitment. Results There was severe adverse event recorded in the study group.All patients improved from moderate to mild category in average 8 days and were discharged in average 9.7 days. None deteriorated to severe stage. All clinical symptoms resolved within 6 days and oxygen supplementation requirement reduced to none within 4.1 days. There wasstatistically significant reduction inCRP (p=0.003), D-Dimer (p=0.049), IL6 (p=0.002)and statistically significant improvement (p=0.001) in SpO2/FiO2 ratio. Change in LDH was borderline statistically not significant (p=0.058).All patients showed significant resolution of bilateral interstitial infiltrates at the end of 10 days. Conclusion Resolved clinical symptoms, improved oxygenation, clearance of infiltrates on Chest X-ray and improvement in biomarkers in a short period with non-progression of the disease showed that IV ozonised saline therapy was safe and effective to prevent disease progression in COVID-19, making it an effective novel therapeutic tool. COVID-19 is a respiratory illness caused due to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). (1) (2) It has led to a global pandemic with a significant mortality rate. Clinically, Covid-19 presents with cough, breathlessness, fever, fatigue, gastrointestinal symptoms, muscle aches, pneumonia, and even death. These symptoms manifest primarily due to a 'cytokine storm' induced by the SARS-CoV-2. (3) In severe cases, it may also lead to systemic inflammation leading to pulmonary fibrosis and systemic organ failure. (4, 5) Currently, the treatment available is symptomatic with general supportive and critical care as there are no approved definitive therapies against SARS-CoV-2. Hypoxia being the main pathology, (6) supplemental oxygen remains the mainstay treatment. Initially, hydroxychloroquine and azithromycin were advised but they were not very effective in severe cases. Antivirals such as oseltamivir, lopinavir-ritonavir were prescribed. Newer antivirals like favipiravir and remdesivir were introduced in the market for achieving better response. Steroids are also advised to curb the inflammation. Tocilizumab is being used to decrease IL6 levels which are exponentially raised in Covid-19. (7) Despite all these measures the world is struggling with high mortality in Researchers are investigating novel multimodal therapeutic approaches for combating this illness. (8) Ozone therapy has tremendous potential for treatment of COVID-19 due to its properties of improved oxygenation, antioxidant, antiviral and anti-inflammatory. (9) Ozone is a paradoxical oxidative agent which can stimulate endogenous antioxidant pathways. It also enhances energy and oxygen supply through blood to tissues, thus reversing hypoxia. (10) It is a powerful antiinflammatory agent that helps to curb the cytokine storm, thus reducing inflammation. (11) It is also an effective antimicrobial, and is known to reduce virulent activity in a preclinical HPV study (12) , as well as in clinical studies treating HIV, (13) herpes zoster, (14) Hepatitis B, (15) (16) (17) (18) and Hepatitis C. (19, 20) It is also used as a treatment for diabetes (21) and respiratory disorders such as asthma (22) and chronic obstructive pulmonary disorder (COPD). (23) Due to its promising ability in viral infections, pulmonary diseases and well-known safety there are several ongoing clinical trials investigating the role of ozone in treating COVID-19. (24) (25) (26) (27) Recent studies published by Shah et al, (28) Franzini et al (29) and Schwartz et al (30) showed significant positive results in patients. We conducted this clinical trial to evaluate the safety and efficacy of ozone therapy in Covid- 19. This unique study shows serial objective data measures throughout 10 days revealing changes happening during the course of ozone therapy. Total 10 patients with confirmed diagnosis of Covid-19 in moderate stage were given IV ozonized saline as an adjuvant along with standard treatment. Patients were monitored for any major or minor adverse events. This clinical trial is a pilot study conducted on 10 patients diagnosed with Covid-19 pneumonia confirmed on qRt-PCR. (Figure 1 ) The primary aim of this study was to evaluate the safety and efficacy of intravenous ozonized saline treatment in moderate stage Covid-19. The study was conducted at NeuroGen Brain and Spine Institute (Dedicated Covid Hospital), Navi Mumbai, India from 23 July 2020 to 13 August 2020 and was registered with the Clinical Trial Registry-India (CTRI) as CTRI/2020/07/026671. An independent data safety and monitoring board (DSMB) was constituted to monitor any adverse events. The Inclusion Criteria of the trial was (a) patients confirmed to be COVID-19 positive by quantitative real time polymerase chain reaction (qRT-PCR) assay, (b) age between 18 to 65 years (c) patients who give written informed consent and (d) patients that meet any one of the criteria of moderate stage according to Table 1 The exclusion criteria of the trial was mild or severe stage according to 10 patients who met the inclusion and exclusion criteria were included in the clinical trial. On these 10 patients alongwith the above tests, specific inflammatory biomarkers such as CRP, IL6, D-Dimer, Ferritin, LDH were conducted on Day 1, 3, 6, 10 before administration of ozonized saline. The ozone gas was generated from an ozone generator for medical use (O3-Ozonics generator, Ozone Forum of India), which is automated and standardized for time, volume and concentration. The ozone generator was manufactured by Ozonics exclusively for Ozone Forum (India). It has a stable and precise ozone concentration variable from 5 mcg/mL to 60 mcg/mL, (tested and certified using ozone analyser). All material in contact with ozone were of medical standards. Feed gas used was pure medical grade oxygen with a variable flow. Ozone-oxygen mixture was bubbled in the saline at 5mcg/ml concentration at 500ml/min flow of oxygen for 20 minutes this achieved 2 μgN/mL dose of ozone at intravenous administration of the solution. For ozonated saline, Ozone was bubbled in 200 ml 0.45% NaCl in a glass bottle for 20 min to saturate saline with Ozone. 200 ml ozonised saline was then immediately administered intravenously over 1 hour at 60 drops per minute. This dose was repeated for each patient once in a day for 8 days. Freshly prepared ozonised saline was administered in each patient daily. Clinical parameters were measured daily by the clinical staff from Day 1 to discharge. Laboratory parameters, Chest X-ray and electrocardiograms were performed before the intervention (Day 1) followed by Day 3, 6 and 10. Data was recorded in the case record form and electronically. The primary outcome measures of this clinical trial were as follows: a. All patients were monitored for major and minor adverse events during treatment, their hospital stay duration and till completion of trial duration i.e. 14 days. Major AE monitored were allergic reaction, anaphylactic reaction, any immediate AE after IV administration of ozonised saline, acute respiratory failure requiring mechanical ventilation, myocardial infarct, heart failure, secondary infection, pulmonary embolism, stroke, arrhythmias, liver failure, renal failure, lifethreatening adverse events and death. Minor adverse events monitored were hematoma, local infection, pain at the site of injection, bleeding at the site of injection, thrombophlebitis, transiently raised LFT and headache. (Table 6 ) A detailed analysis was performed to study the outcome of the intervention. Neutrophil-Lymphocyte Ratio, SpO2/FiO2 ratio, CRP, IL-6, Ferritin, D-Dimer and LDH were analysed. Median of their values was calculated and a line graph with standard error was plotted to study the overall trend in the study population. Resolution of clinical symptoms was evaluated by calculating frequency of symptoms present on Day 1,3,6 and 10 and average number of days taken for resolution of symptoms. Patients chest X-rays were scored using an ordinal scale signifying degree of lung involvement and severity of condition. Paired T-Test was performed on the lab parameters (CRP, IL6, D-Dimer and LDH) and oxygen saturation index SpO2/FiO2. Chest X-ray scores before and after intervention were compared using Wilcoxon sign rank test at the end of 10 days. It was performed in IBM SPSS statistic version 20 and P < 0.05 was considered significant. 10 patients with confirmed diagnosis of moderate Covid-19 were included in this trial. Out of these 9 were males and 1 was female. Age range of the study population was 25 to 59 years with average age as 36.2 years. (Table 2 ) Overall mortality rate in this study population was zero. The frequency of occurrence of clinical symptoms in the 10 patients and average days for these symptoms to resolve was calculated. (Table 4 , Figure 2 ) All patients showed resolution of all the symptoms by Day 10 except 1 patient who had slight inspiratory pleuritic pain which resolved on Day 11. Cough was the last symptom to resolve. Majority symptoms including shortness of breath of all patients resolved by Day 6. Before completion of Day 14, all patients were clinically stable and discharged home. For all laboratory parameters, we calculated the median to demonstrate the trend, as the range of the values recorded in all the patients was varied and large. Procalcitonin (PCT) levels were normal in all patients throughout the study duration. Median of values of serum C-Reactive protein (CRP) was calculated for all patients at Day 1, It was found that there was a statistically significant reduction in IL6, CRP and D-Dimer and statistically significant improvement in SPO2/FiO2 ratio after intervention. However, change in LDH was borderline statistically significant. (Table 5 ) All patients were monitored for major and minor adverse events (AE). (Table 6 to arrest the disease progression along with alleviating the symptoms. This will decrease the need of mechanical ventilatory support and mortality. This clinical trial was conducted to evaluate the safety and efficacy of IV ozonized saline as an adjuvant treatment in Covid-19. Ozone therapy has been extensively employed for treating various chronic diseases like infected wounds, circulatory disorders, geriatric conditions, macular degeneration, viral diseases, rheumatism/arthritis, cancer, severe acute respiratory syndrome and AIDS. (39) (40) (41) . Therapeutic effects of ozone therapy are attributed to its oxygenating, immunomodulatory, anti-inflammatory, oxidation balancing and antiviral properties. (42) Medical Ozone is a mixture of 0.5-5% ozone and 99.5-95% oxygen. Ozone therapy has evolved as a promising therapeutic alternative in various conditions owing to its disinfectant effect and its capacity to transport and release oxygen into tissues. Systemically, ozone can be administered via This was evident from the results of this study which showed rapid increase in SpO2/FiO2 ratio and PaO2/FiO2 ratio. (Figure 9 ,10) Also, supplemental oxygen requirement of patients declined due to this improved oxygenation. Ozone in therapeutic dosage is a hypocoagulant. This property reduces clot formation in Covid-19. All the patients at the time of admission showed areas of ground glass opacification bilaterally in chest X-rays, majority in the peripheral regions while some in lower and mid regions. The findings of chest X-ray in our patients were consistent with previous reports that showed bilateral infiltrates, more in the periphery and lower lobes. (70, 71) These reports also state that the lung involvement and severity of X-ray findings increases as the disease progresses. In this trial, radiological abnormalities were found to have resolved significantly in an average of 8.1 days post ozone therapy. Earliest resolution was seen in some patients within 6 days of starting the intervention. The above findings suggest that early resolution of pulmonary infiltrates by ozone therapy may help to prevent fibrosis in these patients. Additionally, declined disease severity and normalization of oxygen saturation index suggests ceasation of cytokine storm, antiviral effect and improved oxygenation due to ozone therapy. No major adverse events related to procedure or intervention were recorded. The minor adverse events such as pain at bleeding site and headache eventually subsided. Transient increase in LFT was recorded in 8 out of 10 patients. This elevation could be due to antivirals or ozone or combination of both. It is difficult to pin-point any one of these. However, it is noteworthy that the elevation was only transient and resolved with discontinuation of antiviral drugs. Hence, we recommend monitoring LFT when combination treatment of ozone and antivirals is administered. 1 patient who had borderline low sodium levels on admission developed mild dilutional hyponatremia which resolved with salt tablets. The limitation of the study was that it was conducted on a small sample size of 10 patients. Also, the gender distribution of the study population was not balanced. There was only 1 female included in the study. This study did not include patients with chronic uncontrolled illnesses. In this clinical trial, clinical outcomes, laboratory biomarkers and radiological findings showed that Data Availability Statement: Most of the data supporting the findings has been incorporated in the manuscript. Additional data of this study is available from the corresponding author upon request. The author(s) declare(s) that there is no conflict of interest regarding the publication of this paper. The study was funded by Bisleri Charitable Trust The hallmarks of COVID-19 disease A pneumonia outbreak associated with a new coronavirus of probable bat origin Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2 SARS coronavirus papain-like protease induces Egr-1-dependent up-regulation of TGF-β1 via ROS/p38 COVID-19 cytokine storm: The anger of inflammation Hypoxia in COVID-19: Sign of Severity or Cause for Poor Outcomes IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy Treatment options for COVID-19: The reality and challenges Ozone Therapy as a Possible Option in COVID-19 Management The effect of ozone on hypoxia, hemolysis and morphological change of blood from patients with aortic dissection (AD): a preliminary in vitro experiment of ozonated autohemotherapy for treating AD Restoration of normoxia by ozone therapy may control neoplastic growth: a review and a working hypothesis Ozone therapy prevents the onset of dysplasia in HPV16-transgenic mice-A pre-clinical efficacy and safety analysis The immune response behavior in HIV-AIDS patients treated with Ozone therapy for two years Topical ozone therapy: An innovative solution to patients with herpes zoster Combined treatment including ozone therapy of patients with viral hepatitis Ozone Therapy in Patients with Viral Hepatitis C: Ten Years' Experience Preliminary results of ozone therapy as a possible treatment for patients with chronic hepatitis C It is time to integrate conventional therapy by ozone therapy in type-2 diabetes patients Ozone therapy effects on biomarkers and lung function in asthma Oxygen Ozone Therapy in the Treatment of Chronic Obstructive Pulmonary Disease: An Integrative Approach Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19). ChiCTR2000030165. Academy of Medical Engineering and Translational Medicine, Tianjin University.2020-02-24 A randomized controlled trial for the efficacy of ozonated 27. Poscia, R. Oxygen-Ozone as Adjuvant Treatment in Early Control Progression and Modulation of the Gut Microbial Flora (PROBIOZOVID) ClinicalTrials.gov identifier (NCT number Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study) Oxygen-ozone (O2-O3) immunoceutical therapy for patients with COVID-19. Preliminary evidence reported Complementary Application of the Ozonized Saline Solution in Moderate and Severe Patients with Pneumonia Covid-19: Efficacy and Tolerability The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells Clinical features of patients infected with 2019 novel coronavirus in Wuhan Into the Eye of the Cytokine Storm Early Detection of Silent Hypoxia in Covid-19 Pneumonia Using Smartphone Pulse Oximetry COVID-19 infection and oxidative stress: an under-explored approach for prevention and treatment? COVID-19 coagulopathy, thrombosis, and bleeding Hematological findings and complications of COVID-19 Therapeutic management of patients with COVID-19: a systematic review Clinical reversal of root caries using ozone, double-blind, randomised, controlled 18-month trial Decrease of blood cholesterol and stimulation of antioxidative response in cardiopathy patients treated with endovenous ozone therapy Effect of ozone therapy on muscle oxygenation Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19 Ozonized Saline Solution (O3SS): Scientific Foundations Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the Sprotein are affected Ozone (O3) and SARS-CoV-2: Physiological Bases and Their Therapeutic Possibilities According to COVID-19 Evolutionary Stage The Role of Nrf2 in the Antioxidant Cellular Response to Medical Ozone Exposure WFOTs Review on Evidence Based Ozone Therapy. World Federation of Ozone Therapy Nrf2 activation as target to implement therapeutic treatments Mechanisms of Action Involved in Ozone Therapy: Is healing induced via a mild oxidative stress? Arterial thromboembolism associated with COVID-19 and elevated D-dimer levels Diagnosisand treatment of acute pulmonary inflammation in critically ill patients: the role of inflammatory biomarkers Interleukin-6 as a potential biomarker of COVID-19 progression Ozone and oxidation therapies as a solution to the emerging crisis in infectious disease management: a review of current knowledge and experience Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention The Clinical Application of Ozonetherapy The effects of ozone therapy and coenzyme Q(1)(0) combination on oxidative stress markers in healthy subjects Clinical evaluation of potential usefulness of serum lactate dehydrogenase level in follow-up of small cell lung cancer Efficacy and safety of ozone therapy administered by autologous blood transfusion for acute ischemic stroke: study protocol for a multi-center open-label largesample parallel randomized controlled trial Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Prominent coagulation disorder is closely related to inflammatory response and could be as a prognostic indicator for ICU patients with COVID-19 Ozone therapy: A clinical review Ozone therapy as an adjunct to vancomycin enhances bacterial elimination in methicillin resistant Staphylococcus aureus mediastinitis The failure of HIV vaccines: a new autovaccine may overcome some problems Ozone in the treatment of herpes zoster Microbiological aspects of ozone: bactericidal activity and antibiotic/antimicrobial resistance in bacterial strains treated with ozone Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet The indispensable role of chest CT in the detection of coronavirus disease 2019 (COVID-19). European journal of nuclear medicine and molecular imaging